Abstract
We evaluated the utility of longitudinal measures of plasma amyloid-β (Aβ) as a means to identify pre-symptomatic cognitive decline in Alzheimer's disease (AD) when coupled to neuroimaging and neuropsychological parameters. Participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study were grouped based upon cognitive change and changes in measurable levels of neocortical amyloid over 36 months. Participants were classified as those who transitioned for cognitive decline and change in neocortical amyloid, those healthy controls that did not transition, and stable AD participants over 36 months. Comparisons of plasma Aβ levels between the transition and non-transitional groups showed Aβ1-42 and the Aβ1-42/Aβ1-40 ratio were significantly decreased at baseline (p = 0.008 and p = 0.002, respectively) and at 18 months (p = 0.003 and p = 0.004, respectively). Both measures of neocortical amyloid and two previously published composite scores validated the creation of the novel transitional grouping (p < 0.0001). In addition Aβn-42 performed well as a longitudinal prognostic indicator of transition toward cognitive decline, with a significant decrease in the transition group at the 18 month time point (p = 0.01). We d...Continue Reading
Citations
Feb 9, 2018·Nature·Akinori NakamuraKatsuhiko Yanagisawa
Oct 29, 2014·Molecular Psychiatry·L ChengUNKNOWN Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group
Nov 14, 2014·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Naoki KanekoKatsuhiko Yanagisawa
Nov 19, 2014·Neurodegenerative Disease Management·Prita R AsihRalph N Martins
Oct 8, 2015·Journal of Alzheimer's Disease : JAD·Hyeong Jun KimSun Ah Park
Dec 15, 2015·British Journal of Clinical Pharmacology·Thomas H LangenickelIris Rajman
Aug 2, 2017·Journal of Alzheimer's Disease : JAD·Emma LawrenceRoy M Anderson
Sep 28, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Noelia FandosUNKNOWN AIBL Research Group
May 17, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Veer Bala GuptaUNKNOWN AIBL Research Group
Sep 14, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Vincent ChourakiSudha Seshadri
Dec 24, 2019·Journal of Alzheimer's Disease : JAD·Xiaoni WangYing Han
Mar 18, 2020·Neurology·James D DoeckeUNKNOWN AIBL Research Group
Dec 1, 2016·Dementia and Neurocognitive Disorders·Ho Sik ShinSun Ah Park
Aug 1, 2015·Journal of Neural Transmission·Nobuya KitaguchiYukio Yuzawa
Mar 23, 2018·Journal of Alzheimer's Disease : JAD·Ralph N MartinsColin L Masters
Apr 16, 2016·Journal of Alzheimer's Disease : JAD·Cheng-Hui LiuYan-Jiang Wang
Aug 29, 2016·Journal of Alzheimer's Disease : JAD·Virginia Pérez-GrijalbaManuel Sarasa
Apr 7, 2017·Brain : a Journal of Neurology·Blaine R RobertsColin L Masters
Feb 12, 2019·Journal of Alzheimer's Disease : JAD·Li LiMosun Ayan-Oshodi
Nov 21, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Lana FaniM Arfan Ikram
Oct 23, 2020·Aging Cell·Jonah DoustarMaya Koronyo-Hamaoui
Jun 9, 2014·Journal of Neuroimmunology·Alan RembachJames D Doecke